Curatis Holding AGXSWX:CURN +3.51%33 PB Ratio is 2.64 as of Jul. 04, 2026, which is 97% above its 10-year median of 1.34. GuruFocus rates XSWX:CURN with a GF Score™ of 33/100. The stock has 7 warning signs investors should review. Among 921 Drug Manufacturers companies, Curatis Holding AG ranks worse than 62.87% on this metric.
Curatis Holding AG stock PB Ratio (=2.62) is close to 2-year high of 2.8.
The historical rank and industry rank for Curatis Holding AG's PB Ratio or its related term are showing as below:
XSWX:CURN'
s PB Ratio Range Over the Past 10 Years
Min: 1.04 Med: 1.34 Max: 2.8
Current: 2.55
During the past 5 years, Curatis Holding AG's highest PB Ratio was 2.80. The lowest was 1.04. And the median was 1.34.
XSWX:CURN's PB Ratio is ranked worse than 62.87% of 921
companies
in the Drug Manufacturers industry
Industry Median: 1.91
vs XSWX:CURN: 2.55
During the past 12 months, Curatis Holding AG's average Book Value Per Share Growth Rate was -5.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -30.60% per year.
During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of Curatis Holding AG was -30.60% per year. The lowest was -30.60% per year. And the median was -30.60% per year.
Back to Basics: PB Ratio
Curatis Holding AG (XSWX:CURN) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Curatis Holding AG PB Ratio Related Terms
Curatis Holding AG PB Ratio Historical Data
* Premium members only.
The historical data trend for Curatis Holding AG's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Curatis Holding AG's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Curatis Holding AG PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Curatis Holding AG's PB Ratio distribution charts can be found below:
* The bar in red indicates where Curatis Holding AG's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Curatis Holding AG (XSWX:CURN) has a PB Ratio of 2.64 as of Jul. 04, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Curatis Holding AG and its competitors. This is 97% above median its historical median of 1.34. Over the past decade, Curatis Holding AG's PB Ratio has ranged from 1.04 to 2.80. According to the industry distribution chart, Curatis Holding AG ranks #579 out of 921 companies in the Drug Manufacturers industry, placing it in the top 62.9%.
Is Curatis Holding AG's PB Ratio too high?
Curatis Holding AG's current PB Ratio of 2.64 is 97% above median its 10-year median of 1.34. Over the past 10 years, this metric has ranged from a low of 1.04 to a high of 2.80. The Drug Manufacturers industry median PB Ratio is 1.91. Curatis Holding AG's value of 2.64 is 38.2% above this industry median. Based on the distribution chart, Curatis Holding AG ranks #579 out of 921 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Curatis Holding AG has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Curatis Holding AG's PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Curatis Holding AG ranks #579 out of 921 companies for PB Ratio. This places Curatis Holding AG in the lower half of its industry. The industry median PB Ratio is 1.91. Curatis Holding AG's value of 2.64 is 38.2% above this benchmark. Historically, Curatis Holding AG's own PB Ratio has ranged from 1.04 to 2.80 over the past decade. While the company's 10-year median is 1.34 vs. the industry median of 1.91, Curatis Holding AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.91, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Curatis Holding AG's current PB Ratio of 2.64 is 38.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Curatis Holding AG and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curatis Holding AG's current PB Ratio is 2.64, which is 97% above median its own 10-year median of 1.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curatis Holding AG stock overvalued right now?
Curatis Holding AG (XSWX:CURN) has a current PB Ratio of 2.64. The current PB Ratio is 2.64, which is 97% above median its 10-year median of 1.34 and 38.2% above the Drug Manufacturers industry median of 1.91. Curatis Holding AG's overall GF Score™ is 33/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Curatis Holding AG (XSWX:CURN), the current PB Ratio is 2.64 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Curatis Holding AG is a specialty pharmaceutical Company with two-pillar. On one hand, the Company trades and distributes specialty medicines in the rare disease and specialty medicines space i.e. acquires, licenses, distributes and promotes pharmaceutical products for the treatment and/or prevention of rare and specialty diseases in Switzerland. On the other hand, it is a drug development Company with a pipeline of product candidates, also predominantly in the orphan drug space.
33GF Score
Get the complete analysis for XSWX:CURN
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:CURN has been successfully added to your 
